NVG-291 Phase 1 Results and Phase 1b/2a Study Design in Individuals with Spinal Cord Injury

To provide an update on the development of NVG-291 for spinal cord injury (SCI). There is a high unmet need for treatments to repair damage after SCI. A Phase 1 safety trial of NVG-291 (a receptor protein tyrosine phosphatase sigma peptide mimetic) in 70 healthy subjects supports a Phase 1b/2a efficacy/safety trial in individuals with SCI. Doses tested overlap with and exceed equivalent efficacious doses in animal models of acute/chronic SCI.
Source: Archives of Physical Medicine and Rehabilitation - Category: Rehabilitation Authors: Tags: Oral Presentation 2508967 Source Type: research